{"nctId":"NCT01754714","briefTitle":"Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group","startDateStruct":{"date":"2012-12"},"conditions":["Non Alcoholic Fatty Liver Disease"],"count":108,"armGroups":[{"label":"1000 mg SAMe (S-adenosyl-L-methionine)","type":"EXPERIMENTAL","interventionNames":["Drug: SAMe 1000 mg"]},{"label":"1500 mg SAMe","type":"EXPERIMENTAL","interventionNames":["Drug: SAMe 1500 mg"]},{"label":"2000 mg SAMe","type":"EXPERIMENTAL","interventionNames":["Drug: SAMe 2000 mg"]},{"label":"No treatment","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"SAMe 1000 mg","otherNames":[]},{"name":"SAMe 1500 mg","otherNames":[]},{"name":"SAMe 2000 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Subjects with non-alcoholic steatohepatitis based on histology in medical history within the last 3 years\n* Subjects in a stable metabolic condition since histology for NASH (Non-alcoholic Steatohepatitis)\n\nExclusion Criteria\n\n* Subjects with extrahepatic biliary obstruction\n* Subjects with primary sclerosing cholangitis (PSC)\n* Subjects with primary biliary cirrhosis (PBC)\n* Any form of malignancy within the past 5 years and/or basal cell carcinoma and squamous cell carcinoma of the skin within the past two years\n* History of active substance abuse (oral, inhaled or injected) within one year prior to the study\n* Subjects with renal impairment (creatinine level of \\>2.0 mg/dL)\n* Subjects with a known hypersensitivity to the active substance (ademetionine) or methionine or to any of the inactive ingredients\n* Subjects with known genetic defects affecting the methionine cycle and/or causing homocystinuria and/or hyperhomocysteinemia (e.g., cystathionine beta-synthase deficiency, Vitamin B12 metabolism defect)\n* Subjects on total parenteral nutrition in the year prior to screening\n* Subjects after or planned for bariatric surgery (jejunoileal bypass or gastric weight loss surgery)\n* Extrahepatic cholestasis (proven by ultrasound)\n* Subjects with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \\> 5 upper limit of normal (ULN)\n* Subject with serum total bilirubin (STB) \\> 5 ULN\n* Subjects after liver transplantation and subjects on the waiting list for liver transplantation\n* Subjects with any of the following disease in medical history:\n* Viral hepatitis (serum positive HBcAb (hepatitis B core antibody) or Hepatitis C Virus (HCV) ribonucleic acid (RNA)\n* Evidence of autoimmune liver disease\n* Wilson's disease\n* Hemochromatosis\n* Alpha-1-antitrypsin deficiency\n* Known positivity for antibody to human immunodeficiency virus (HIV)\n* Known heart failure of New York heart Association class 3 or 4\n* Current or history of significant alcohol consumption for a period of more than three consecutive months within five years prior to screening (significant alcohol consumption is defined as \\> 3 U (unit)/day for men and \\> 2 U/day for women, on average) or binge drinking or inability to reliably quantify alcohol consumption.\n* Clinical or histological evidence of cirrhosis F4\n* Subjects with history of biliary diversion\n* Subjects with uncontrolled diabetes mellitus defined by HbA1c (hemoglobin A1c) \\> 8.0 % at screening\n* Concomitant medication of B12, folate, betaine or choline\n* Concomitant treatment with glitazone within the past year prior to the study\n* Subjects with known folate or B12 deficiency\n* BMI (body mass index) \\> 40 kg/m2\n* History of major depression diagnostic and statistical manual of mental disorders (DSM-IV) or bipolar disease\n* Women of childbearing potential: positive urine pregnancy test during screening or unwillingness to use an effective form of birth control during the study.\n* Breastfeeding women\n* Any condition that, in the opinion of the investigator, does not justify the patient's inclusion into the study\n* Investigational drug intake within one month prior to the study\n* Active, serious medical disease with likely life-expectancy less than five years\n* Uncooperative attitude or reasonable likelihood for non-compliance with the protocol or any other reason that, in the investigator's opinion, prohibits the inclusion of the subject into the study\n* Legal incapacity or limited legal capacity, or who are incarcerated.\n* Inability to return for scheduled visits.\n* Inability to understand and follow the requirements of the protocol in the local language","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Methionine Elimination Half-life Measured in Blood.","description":"After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.29","spread":"1.86"},{"groupId":"OG001","value":"4.66","spread":"1.57"},{"groupId":"OG002","value":"4.25","spread":"1.64"},{"groupId":"OG003","value":"4.26","spread":"1.44"}]}]}]},{"type":"SECONDARY","title":"Fasting Methionine Concentration of Average Methionine Concentration Versus Time Curve.","description":"After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.02","spread":"0.92"},{"groupId":"OG001","value":"3.81","spread":"0.67"},{"groupId":"OG002","value":"5.68","spread":"10.13"},{"groupId":"OG003","value":"5.62","spread":"8.53"}]}]}]},{"type":"SECONDARY","title":"13 Carbon (Natural, Stable Isotope of Carbon) Methionine Breath Test","description":"parameters cumulative percentage dose of 13 carbon recovered after 30, 60, 90 minutes (cPDR30, cPDR60, cPDR 90) will be evaluated","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"0.73"},{"groupId":"OG001","value":"0.77","spread":"0.51"},{"groupId":"OG002","value":"0.88","spread":"0.66"},{"groupId":"OG003","value":"0.69","spread":"0.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.66","spread":"1.99"},{"groupId":"OG001","value":"3.49","spread":"1.74"},{"groupId":"OG002","value":"3.61","spread":"1.78"},{"groupId":"OG003","value":"2.98","spread":"1.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.69","spread":"2.75"},{"groupId":"OG001","value":"6.60","spread":"2.56"},{"groupId":"OG002","value":"6.68","spread":"2.48"},{"groupId":"OG003","value":"5.74","spread":"2.56"}]}]}]},{"type":"SECONDARY","title":"Hepatic Panel (Liver Laboratory Parameters)","description":"Serum Total Bilirubin (STB), Serum Conjugated Bilirubin (SCB), liver-alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), Gamma Glutamyl Transpeptidase (GGT)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"7.9"},{"groupId":"OG001","value":"-0.1","spread":"13.7"},{"groupId":"OG002","value":"3.4","spread":"24.1"},{"groupId":"OG003","value":"-6.0","spread":"16.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","spread":"19.5"},{"groupId":"OG001","value":"-6.3","spread":"23.5"},{"groupId":"OG002","value":"-4.9","spread":"32.2"},{"groupId":"OG003","value":"-11.9","spread":"33.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"15.7"},{"groupId":"OG001","value":"-3.0","spread":"16.5"},{"groupId":"OG002","value":"-1.2","spread":"10.7"},{"groupId":"OG003","value":"-11.6","spread":"27.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"33.7"},{"groupId":"OG001","value":"-10.6","spread":"62.7"},{"groupId":"OG002","value":"-2.7","spread":"35.7"},{"groupId":"OG003","value":"-12.3","spread":"48.1"}]}]}]},{"type":"SECONDARY","title":"Metabolic Panel (Metabolic Laboratory Parameters)","description":"Fasting lipid profile (cholesterol, HDL (High Density Lipoprotein), LDL (Low Density Lipoprotein)), amino acid profile, homeostasis model assessment (HOMA-R) and fasting glucose.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.131","spread":"0.593"},{"groupId":"OG001","value":"0.046","spread":"0.921"},{"groupId":"OG002","value":"-0.265","spread":"0.601"},{"groupId":"OG003","value":"-0.134","spread":"0.659"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.094","spread":"0.166"},{"groupId":"OG001","value":"-0.046","spread":"0.254"},{"groupId":"OG002","value":"-0.098","spread":"0.169"},{"groupId":"OG003","value":"-0.075","spread":"0.188"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.125","spread":"0.452"},{"groupId":"OG001","value":"0.182","spread":"0.762"},{"groupId":"OG002","value":"-0.202","spread":"0.589"},{"groupId":"OG003","value":"-0.112","spread":"0.558"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.837","spread":"13.232"},{"groupId":"OG001","value":"0.127","spread":"3.763"},{"groupId":"OG002","value":"-1.549","spread":"13.321"},{"groupId":"OG003","value":"3.432","spread":"10.837"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.068","spread":"0.968"},{"groupId":"OG001","value":"0.490","spread":"1.486"},{"groupId":"OG002","value":"-0.163","spread":"1.009"},{"groupId":"OG003","value":"-0.121","spread":"1.610"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)","description":"Cytokine profile ( Interleukin-6, IL-8, IL-10 (IL), Tumor Necrosis Factor (TNF -α), monocyte chemoattractant protein (MCP-1), and Granulocyte-colony stimulating factor (G-CSF ).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0603","spread":"2.0263"},{"groupId":"OG001","value":"-0.9254","spread":"6.4599"},{"groupId":"OG002","value":"-1.3194","spread":"4.5779"},{"groupId":"OG003","value":"0.1597","spread":"1.6243"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.41","spread":"41.07"},{"groupId":"OG001","value":"0.65","spread":"13.37"},{"groupId":"OG002","value":"-78.73","spread":"187.51"},{"groupId":"OG003","value":"-6.17","spread":"16.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.270","spread":"NA"},{"groupId":"OG001","value":"-0.045","spread":"0.106"},{"groupId":"OG002","value":"-0.300","spread":"NA"},{"groupId":"OG003","value":"1.600","spread":"1.146"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.127","spread":"0.414"},{"groupId":"OG001","value":"-1.083","spread":"4.782"},{"groupId":"OG002","value":"-0.601","spread":"2.136"},{"groupId":"OG003","value":"-0.187","spread":"1.114"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.75","spread":"154.75"},{"groupId":"OG001","value":"-20.60","spread":"79.71"},{"groupId":"OG002","value":"-40.15","spread":"96.21"},{"groupId":"OG003","value":"-44.51","spread":"114.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.0","spread":"52.8"},{"groupId":"OG001","value":"-0.5","spread":"9.7"},{"groupId":"OG002","value":"20.0","spread":"NA"},{"groupId":"OG003","value":"NA","spread":"NA"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Fibrosis and Apoptosis Markers (Fibrosis and Apoptosis Laboratory Markers)","description":"Non-invasive test for liver disease (ActiTest)/Fibrotest\n\nFibroTest® : diagnoses hepatic fibrosis ActiTest® : assesses viral necro-inflammatory activity Scores between 0 and 1, the higher the score the worse\n\nThe FibroTest score is calculated from the results of a six-parameter blood test, combining six serum markers with the age and gender of the patient:Alpha-2-macroglobulin, Haptoglobin, Apolipoprotein A1, Gamma-glutamyl transpeptidase (GGT), Total bilirubin, and Alanine transaminase (ALT). ALT is used in a second assessment called ActiTest that is part of FibroTest.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.017","spread":"0.098"},{"groupId":"OG001","value":"-0.022","spread":"0.137"},{"groupId":"OG002","value":"-0.002","spread":"0.168"},{"groupId":"OG003","value":"-0.042","spread":"0.096"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.036","spread":"0.097"},{"groupId":"OG001","value":"0.028","spread":"0.093"},{"groupId":"OG002","value":"0.050","spread":"0.125"},{"groupId":"OG003","value":"0.020","spread":"0.068"}]}]}]},{"type":"SECONDARY","title":"The Metabolic Clearance Rate Measured in the Blood.","description":"After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4.5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.86","spread":"2.93"},{"groupId":"OG001","value":"9.83","spread":"3.27"},{"groupId":"OG002","value":"10.05","spread":"4.32"},{"groupId":"OG003","value":"8.23","spread":"2.30"}]}]}]},{"type":"SECONDARY","title":"Methionine Volume of Distribution at Week 7 (L)","description":"After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4, 5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.40","spread":"18.43"},{"groupId":"OG001","value":"62.84","spread":"14.04"},{"groupId":"OG002","value":"64.58","spread":"17.77"},{"groupId":"OG003","value":"8.23","spread":"53.98"}]}]}]},{"type":"SECONDARY","title":"13 Carbon (Natural, Stable Isotope of Carbon) Methionine Breath Test","description":"Peak","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0972","spread":"0.0062"},{"groupId":"OG001","value":"1.0964","spread":"0.0052"},{"groupId":"OG002","value":"1.0964","spread":"0.0053"},{"groupId":"OG003","value":"1.0949","spread":"0.0045"}]}]}]},{"type":"SECONDARY","title":"13 Carbon (Natural, Stable Isotope of Carbon) Methionine Breath Test","description":"Time to peak","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","spread":null},{"groupId":"OG001","value":"70.0","spread":null},{"groupId":"OG002","value":"70.0","spread":null},{"groupId":"OG003","value":"70.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Metabolic Panel (Metabolic Laboratory Parameters)","description":"Fasting plasma insulin","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"191.0"},{"groupId":"OG001","value":"-13.6","spread":"115.5"},{"groupId":"OG002","value":"-13.1","spread":"248"},{"groupId":"OG003","value":"69.1","spread":"309.0"}]}]}]},{"type":"SECONDARY","title":"Metabolic Panel (Metabolic Laboratory Parameters)","description":"glycosylated hemoglobin (HbA1c)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.28"},{"groupId":"OG001","value":"-0.06","spread":"0.36"},{"groupId":"OG002","value":"-0.05","spread":"0.32"},{"groupId":"OG003","value":"0.02","spread":"0.33"}]}]}]},{"type":"SECONDARY","title":"Metabolic Panel (Metabolic Laboratory Parameters)","description":"Adiponectin","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.754","spread":"4.191"},{"groupId":"OG001","value":"0.425","spread":"1.199"},{"groupId":"OG002","value":"0.219","spread":"1.661"},{"groupId":"OG003","value":"0.045","spread":"1.515"}]}]}]},{"type":"SECONDARY","title":"Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)","description":"C-reactive Protein (CRP)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":"15.51"},{"groupId":"OG001","value":"-0.80","spread":"14.90"},{"groupId":"OG002","value":"-8.02","spread":"20.40"},{"groupId":"OG003","value":"-4.80","spread":"12.8"}]}]}]},{"type":"SECONDARY","title":"Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)","description":"glutathione in erythrocytes","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"2.06"},{"groupId":"OG001","value":"-0.21","spread":"1.01"},{"groupId":"OG002","value":"0.05","spread":"1.41"},{"groupId":"OG003","value":"-0.30","spread":"1.33"}]}]}]},{"type":"SECONDARY","title":"Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)","description":"oxidative stress marker (isoprostane level)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.223","spread":"0.801"},{"groupId":"OG001","value":"0.116","spread":"0.699"},{"groupId":"OG002","value":"0.290","spread":"0.691"},{"groupId":"OG003","value":"-0.223","spread":"0.641"}]}]}]},{"type":"SECONDARY","title":"Fibrosis and Apoptosis Markers (Fibrosis and Apoptosis Laboratory Markers)","description":"Caspase-cleaved cytokeratin (CK 18)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-126.8","spread":"401.1"},{"groupId":"OG001","value":"-136.6","spread":"257.3"},{"groupId":"OG002","value":"-47.0","spread":"157.3"},{"groupId":"OG003","value":"-143.2","spread":"532.5"}]}]}]},{"type":"SECONDARY","title":"Fibrosis and Apoptosis Markers (Fibrosis and Apoptosis Laboratory Markers)","description":"Hyaluronic acid","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.67","spread":"48.52"},{"groupId":"OG001","value":"2.03","spread":"32.26"},{"groupId":"OG002","value":"9.40","spread":"59.63"},{"groupId":"OG003","value":"3.02","spread":"46.56"}]}]}]},{"type":"SECONDARY","title":"Area Under Curve (AUC) of Average Methionine Concentration Versus Time Curve","description":"After the methionine load, blood samples will be obtained at 0.5, 1, 1.5, 3, 4, 5, 6, 7.5 and 9 hours. Plasma will be analyzed for methionine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"440.09","spread":"149.96"},{"groupId":"OG001","value":"399.30","spread":"148.90"},{"groupId":"OG002","value":"425.24","spread":"231.88"},{"groupId":"OG003","value":"460.57","spread":"135.63"}]}]}]},{"type":"SECONDARY","title":"Hepatic Panel (Liver Laboratory Parameters)","description":"ALT/AST ratio","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.23"},{"groupId":"OG001","value":"0.01","spread":"0.21"},{"groupId":"OG002","value":"0.03","spread":"0.18"},{"groupId":"OG003","value":"-0.01","spread":"0.27"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["DIARRHOEA","Abdominal Pain","Headache","Fatigue"]}}}